Literature DB >> 8557362

A nontoxic cholera enterotoxin (CT) analog is chimeric with regard to both epitypes of CT-B subunits, CT-B-1 and CT-B-2.

M Boesman-Finkelstein1, J W Peterson, L S Thai, R A Finkelstein.   

Abstract

The gene encoding a nontoxic analog, CT-2*, of cholera enterotoxin (CT) with attenuating codon substitutions in the A subunit was introduced into the attenuated Vibrio cholerae classical biotype mutant candidate vaccine strain CVD103, which produces the B subunit (but not the A subunit) of CT-1. The recombinant strain produces a chimeric nontoxic analog holotoxin containing both CT-B-1 and CT-B-2 subunits. This offers potential advantages over CVD103 in the induction of immunity against E1 Tor biotype and V. cholerae O139 strains which produce CT-B-2. The recombinant protein may also be useful in polysaccharide-protein conjugate vaccines against both O1 and O139 serovars of V. cholerae.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557362      PMCID: PMC173766          DOI: 10.1128/iai.64.1.346-348.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

2.  Studies on toxinogenesis in Vibrio cholerae. I. Isolation of mutants with altered toxinogenicity.

Authors:  R A Finkelstein; M L Vasil; R K Holmes
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

3.  Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice.

Authors:  K Fujita; R A Finkelstein
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

4.  Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Authors:  M R Fontana; R Manetti; V Giannelli; C Magagnoli; A Marchini; R Olivieri; M Domenighini; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

Review 5.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Study of epitopes of cholera enterotoxin-related enterotoxins by checkerboard immunoblotting.

Authors:  M Kazemi; R A Finkelstein
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

7.  Development of a purified cholera toxoid. I. Purification of toxin.

Authors:  R S Rappaport; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

8.  Checkerboard immunoblotting recognizes twenty epitopes among the B subunit proteins of the cholera enterotoxin family.

Authors:  Z H Qu; R A Finkelstein
Journal:  Electrophoresis       Date:  1993-09       Impact factor: 3.535

9.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

10.  Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose.

Authors:  Y Uesaka; Y Otsuka; Z Lin; S Yamasaki; J Yamaoka; H Kurazono; Y Takeda
Journal:  Microb Pathog       Date:  1994-01       Impact factor: 3.738

View more
  2 in total

1.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Authors:  Pallavi R Manuri; Bharti Nehete; Pramod N Nehete; Rose Reisenauer; Seth Wardell; Amy N Courtney; Ratish Gambhira; Dakshyani Lomada; Ashok K Chopra; K Jagannadha Sastry
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

2.  Cholera toxin B subunit activates arachidonic acid metabolism.

Authors:  J W Peterson; R A Finkelstein; J Cantu; D L Gessell; A K Chopra
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.